Laura Poliseno

List of Publications by Year
in descending order

58	12,063	304743	175258
papers	citations	22 h-index	52 g-index

62	62	62	16057
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System. Thyroid, 2021, 31, 1056-1066.	4.5	3
2	High-Throughput Identification of miRNAâ€“Target Interactions in Melanoma Using miR-CATCHv2.0. Methods in Molecular Biology, 2021, 2265, 487-512.	0.9	0
3	A eutherian-specific microRNA controls the translation of Satb2 in a model of cortical differentiation. Stem Cell Reports, 2021, 16, 1496-1509.	4.8	8
4	Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma. Journal of Visualized Experiments, 2021, , .	0.3	1
5	CRISPR/Cas Technologies Applied to Pseudogenes. Methods in Molecular Biology, 2021, 2324, 265-284.	0.9	0
6	In Vivo Silencing/Overexpression of lncRNAs by CRISPR/Cas System. Methods in Molecular Biology, 2021, 2348, 205-220.	0.9	3
7	Proteomics pipeline for phosphoenrichment and its application on a human melanoma cell model. Talanta, 2020, 220, 121381.	5.5	7
8	PTENP1 is a ceRNA for PTEN: itâ€™s CRISPR clear. Journal of Hematology and Oncology, 2020, 13, 73.	17.0	13
9	Inducible modulation of miR-204 levels in a zebrafish melanoma model. Biology Open, 2020, 9, .	1.2	3
10	476 GJB5 association with BRAF mutation and survival in cutaneous melanoma. Journal of Investigative Dermatology, 2019, 139, S296.	0.7	0
11	Biosafety and Biokinetics of Noble Metals: The Impact of Their Chemical Nature. ACS Applied Bio Materials, 2019, 2, 4464-4470.	4.6	49
12	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. Pharmacogenomics Journal, 2019, 19, 455-464.	2.0	5
13	Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. Oncogene, 2019, 38, 3756-3762.	5.9	30
14	MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2111-2124.	3.8	14
15	Systematic evaluation of the microRNAome through miR-CATCHv2.0 identifies positive and negative regulators of BRAF-X1 mRNA. RNA Biology, 2019, 16, 865-878.	3.1	10
16	Development of a yeast-based system to identify new hBRAFV600E functional interactors. Oncogene, 2019, 38, 1355-1366.	5.9	8
17	Biological role of miR-204 and miR-211 in melanoma. Oncoscience, 2018, 5, 248-251.	2.2	15
18	The landscape of BRAF transcript and protein variants in human cancer. Molecular Cancer, 2017, 16, 85.	19.2	22

#	Article	IF	Citations
19	Ensemble Modeling Approach Targeting Heterogeneous RNA-Seq data: Application to Melanoma Pseudogenes. Scientific Reports, 2017, 7, 17344.	3.3	2
20	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget, 2017, 8, 25395-25417.	1.8	64
21	Abstract LB-282: Two different strategies of delivery CRISPR/Cas9 system to gene edit rs4644 SNP inLGALS3gene. , 2017, , .		0
22	Methods for the Identification of PTEN-Targeting MicroRNAs. Methods in Molecular Biology, 2016, 1388, 111-138.	0.9	3
23	Alkaline Phosphatase-Positive Immortal Mouse Embryo Fibroblasts Are Cells in a Transitional Reprogramming State Induced to Face Environmental Stresses. Genetics & Epigenetics, 2015, 7, GEG.S27696.	2.5	1
24	Pseudogenes in Human Cancer. Frontiers in Medicine, 2015, 2, 68.	2.6	92
25	Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. Annals of Oncology, 2015, 26, vi37.	1.2	0
26	P-198 Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib. Annals of Oncology, 2015, 26, iv57.	1.2	1
27	Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	9.4	24
28	PTEN ceRNA networks in human cancer. Methods, 2015, 77-78, 41-50.	3.8	121
29	Identification of BRAF 3â€²UTR Isoforms in Melanoma. Journal of Investigative Dermatology, 2015, 135, 1694-1697.	0.7	12
30	Long non-coding RNAs in cancer: implications for personalized therapy. Cellular Oncology (Dordrecht), 2015, 38, 17-28.	4.4	92
31	Pseudogenes. Methods in Molecular Biology, 2014, 1167, v.	0.9	5
32	MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. Cell, 2013, 154, 311-324.	28.9	417
33	Hedgehog Pathway Blockade Inhibits Melanoma Cell Growth in Vitro and in Vivo. Pharmaceuticals, 2013, 6, 1429-1450.	3.8	40
34	Histology-Specific MicroRNA Alterations in Melanoma. Journal of Investigative Dermatology, 2012, 132, 1860-1868.	0.7	46
35	Pseudogenes: Newly Discovered Players in Human Cancer. Science Signaling, 2012, 5, re5.	3.6	125
36	Abstract 425: Targeting embryonic signaling pathways in melanoma. , 2012, , .		0

#	Article	IF	Citations
37	A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?. Cell, 2011, 146, 353-358.	28.9	5,954
38	Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs. Cell, 2011, 147, 344-357.	28.9	926
39	Deletion of PTENP1 Pseudogene in Human Melanoma. Journal of Investigative Dermatology, 2011, 131, 2497-2500.	0.7	99
40	The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma. PLoS ONE, 2011, 6, e25264.	2.5	60
41	microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO Journal, 2011, 30, 1990-2007.	7.8	228
42	Integrative Genomics Identifies Molecular Alterations that Challenge the Linear Model of Melanoma Progression. Cancer Research, 2011, 71, 2561-2571.	0.9	57
43	Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations.. Journal of Clinical Oncology, 2011, 29, 8540-8540.	1.6	2
44	A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature, 2010, 465, 1033-1038.	27.8	2,133
45	Identification of the miR-106b ~ 25 MicroRNA Cluster as a Proto-Oncogenic PTEN -Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation. Science Signaling, 2010, 3, ra29.	3.6	390
46	The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.. Journal of Clinical Oncology, 2010, 28, 8553-8553.	1.6	0
47	Preclinical analyses of a new gamma-secretase inhibitor targeting notch signaling in melanoma.. Journal of Clinical Oncology, 2010, 28, 8546-8546.	1.6	0
48	LRF Is an Essential Downstream Target of GATA1 in Erythroid Development and Regulates BIM-Dependent Apoptosis. Developmental Cell, 2009, 17, 527-540.	7.0	97
49	The Proto-Oncogene LRF Is under Post-Transcriptional Control of MiR-20a: Implications for Senescence. PLoS ONE, 2008, 3, e2542.	2.5	79
50	Resting smooth muscle cells as a model for studying vascular cell activation. Tissue and Cell, 2006, 38, 111-120.	2.2	16
51	miRNAs Regulate miRNAs: Coordinated Transcriptional and Post-Transcriptional Regulation. Cell Cycle, 2006, 5, 2473-2476.	2.6	33
52	MicroRNAs modulate the angiogenic properties of HUVECs. Blood, 2006, 108, 3068-3071.	1.4	693
53	Identification of active siRNAs against IGF-IR of porcine coronary smooth muscle cells in a heterologous cell line. International Journal of Molecular Medicine, 2005, 15, 713.	4.0	1
54	The Energy Profiling of Short Interfering RNAs Is Highly Predictive of Their Activity. Oligonucleotides, 2004, 14, 227-232.	2.7	16

#	Article	IF	Citations
55	Bcl2-low-expressing MCF7 cells undergo necrosis rather than apoptosis upon staurosporine treatment. Biochemical Journal, 2004, 379, 823-832.	3.7	9
56	RNA-Based Drugs: From RNA Interference to Short Interfering RNAs. Current Pharmaceutical Biotechnology, 2004, 5, 361-368.	1.6	8
57	Bcl2-negative MCF7 cells overexpress p53: implications for the cell cycle and sensitivity to cytotoxic drugs. Cancer Chemotherapy and Pharmacology, 2002, 50, 127-130.	2.3	14
58	The Sensitivity of MCF10A Breast Epithelial Cells to Alkylating Drugs is Enhanced by the Inhibition of O6-Methylguanine-DNA Methyltransferase Transcription with a Synthetic Double Strand DNA Oligonucleotide. Breast Cancer Research and Treatment, 2002, 73, 207-213.	2.5	3